Heat shock proteins (Hsps) are overexpressed in various human cancers and play roles in tumor cell proliferation, differentiation, invasion, metastasis, and immune recognition. While Hsp levels are not informative for diagnosis, they serve as biomarkers for carcinogenesis and indicate tumor differentiation and aggressiveness. Hsp expression is associated with poor prognosis in several cancers, including gastric, liver, and prostate carcinomas, and osteosarcomas. Hsp70 is linked to poor prognosis in breast, endometrial, and cervical cancers. Hsp expression may predict treatment response, such as resistance to chemotherapy in breast cancer and better response in osteosarcomas. Hsps are targeted in therapy through pharmacological modification of their expression or molecular chaperone activity and as adjuvants in anticancer vaccines. Hsps are also involved in tumor progression and response to therapy, making them promising targets for cancer treatment. Hsp27 and Hsp70 are particularly important in this context. Hsp27 is associated with poor prognosis in several cancers, while Hsp70 is linked to poor prognosis in some cancers but better prognosis in others. Hsps are also involved in immune responses, acting as adjuvants to enhance immune recognition of tumor antigens. Hsp-based vaccines have shown promise in treating cancers such as renal cancer and melanoma. However, the exact mechanisms of Hsp involvement in cancer remain unclear, and more research is needed to fully understand their role in cancer diagnosis, prognosis, and treatment. The field of Hsps in cancer is currently in its early stages, with significant contributions to both basic and clinical research.Heat shock proteins (Hsps) are overexpressed in various human cancers and play roles in tumor cell proliferation, differentiation, invasion, metastasis, and immune recognition. While Hsp levels are not informative for diagnosis, they serve as biomarkers for carcinogenesis and indicate tumor differentiation and aggressiveness. Hsp expression is associated with poor prognosis in several cancers, including gastric, liver, and prostate carcinomas, and osteosarcomas. Hsp70 is linked to poor prognosis in breast, endometrial, and cervical cancers. Hsp expression may predict treatment response, such as resistance to chemotherapy in breast cancer and better response in osteosarcomas. Hsps are targeted in therapy through pharmacological modification of their expression or molecular chaperone activity and as adjuvants in anticancer vaccines. Hsps are also involved in tumor progression and response to therapy, making them promising targets for cancer treatment. Hsp27 and Hsp70 are particularly important in this context. Hsp27 is associated with poor prognosis in several cancers, while Hsp70 is linked to poor prognosis in some cancers but better prognosis in others. Hsps are also involved in immune responses, acting as adjuvants to enhance immune recognition of tumor antigens. Hsp-based vaccines have shown promise in treating cancers such as renal cancer and melanoma. However, the exact mechanisms of Hsp involvement in cancer remain unclear, and more research is needed to fully understand their role in cancer diagnosis, prognosis, and treatment. The field of Hsps in cancer is currently in its early stages, with significant contributions to both basic and clinical research.